Vident Investment Advisory’s Autolus Therapeutics AUTL Stock Holding History

Vident Investment Advisory’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-111,832	Closed	-$670K	–	842
2020 Q1	$670K	Sell	111,832 -7,034	-6%	-$65K	0.04%	502
2019 Q4	$1.57M	Buy	118,866 +30,953	+35%	+$405K	0.1%	323
2019 Q3	$1.09M	Sell	87,913 -2,512	-3%	-$33.2K	0.1%	166
2019 Q2	$1.46M	Buy	+90,425	New	+$2.02M	0.12%	124

Other funds holding AUTL

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vident Investment Advisory's AUTL Position: Q2 2020 in Review

Vident Investment Advisory sold out of Autolus Therapeutics (AUTL) in Q2 2020, closing a stake of 111,832 shares — an estimated $670K sold.

Vident Investment Advisory first reported a position in AUTL in Q2 2019 and held it in 4 quarters. The position peaked at $1.57M in Q4 2019. 50 funds tracked by Wall St. Rank hold AUTL as of Q2 2020.

Vident Investment Advisory reported no remaining Autolus Therapeutics position as of Q2 2020 after selling out during the quarter.
Vident Investment Advisory sold 111,832 Autolus Therapeutics shares in Q2 2020, an estimated $670K.
Vident Investment Advisory first reported a position in Autolus Therapeutics in Q2 2019 and held it in 4 quarters.
Vident Investment Advisory's Autolus Therapeutics position peaked at $1.57M in Q4 2019.
50 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2020.

Based on Vident Investment Advisory's 13F filing for Q2 2020, filed 17 Jul 2020.